Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03559517 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT03559517 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 30 participants.
The verdict
NCT03559517, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
Interventions
- OTHER Placebo
- BIOLOGICAL Ontamalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03559517
The ClinicalTrials.gov registry entry for NCT03559517 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03559517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03559517 about?
NCT03559517 is a clinical study titled "Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)". The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
What is the current status of trial NCT03559517?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2018-08-29. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT03559517?
The interventions under investigation include: Placebo (OTHER), Ontamalimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03559517?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.